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Summary.-Antibodies directed against the antigens released from viable tumour
cells during growth have been raised by cross-immunization of immunocompetent
hairylitter-mates with serumfrom nude micebearing pancreatic tumourxenografts.
Antisera raised against the components released from a primary pancreatic tumour
xenograft (WB) or from a tumour cell-line xenograft (GER) showed a titre > 1:625
against cultured pancreatic tumour cells by an 1125-binding assay. Five out of 14 ofthe
hairy litter-mates immunized with serum from the same tumour (GER) produced
antisera that bound more strongly to pancreatic cancer cells than to 13 other non-
pancreatic cell lines (binding ratio >2). Absorption of the antisera with pure CEA
reduced the level of binding by 11-25% without affecting the specificity for pancreatic
tumour cells. The antibody response could be completely removed by absorption
with pancreatic tumour cells, whereas 50% and 18% of the activity remained after
absorption with normal pancreas homogenate and a mixed non-pancreatic tumour-
cell pool, respectively. Immunofluorescent staining of pancreatic tumour sections
indicated that the antibody was localized on the membrane of ductular epithelial
cells. Challenge ofimmunocompetent mice using this procedure has produced a poly-
specific antiserum with signs of selectivity for the circulating antigens released from
pancreatic cancer cells, and may provide a route to the production ofantibody against
specific tumour components.
CANCER CELLS may evade immuno-
logical recognition by shedding their
surface antigens (Alexander, 1974; Bald-
win et al., 1974). These antigens are glyco-
proteins or whole plasma membrane frag-
ments (De Broe et al., 1977) which circu-
late in a free state or complex with host
immunoglobulins (Sjogren et al., 1971;
Bowen et al., 1975). Although a number
of groups have demonstrated the release
of human and animal cell-surface proteins
into the serum of tumour-bearing animals
(Jamasbi et al., 1978; Nordquist et al.,
1978; Rao & Bonavida, 1977; Primus et al.,
1976) a study ofthis process is complicated
by the host's immune system.
The availability ofhuman tumour xeno-
grafts grown in nude mice provides a
model in which human proteins are re-
leased into the blood stream ofanimmune-
deficient animal. The aim of this study
was to ascertain whether an antibody
response against these circulating human
tumour antigens could be achieved by
injection of serum from tumour-bearing
animals into immunocompetent hairy
litter-mates. Using this immunization
regime it should be possible to produce a
polyspecific antiserum recognising both
tumour and normal components that are
shed from the cell surface. The possibility
of selecting antibodies to specific circulat-
ing tumour components by eventually
fusing the spleen cells ofthese animals with
a myeloma to produce monoclonal anti-
bodies should be applicable to all solid
tumours, and may have considerable
clinical application.ANTIBODIES TO HUMAN TUMOUR XENOGRAFTS
MATERIALS AND METHODS
Animals.-Four-6-w eek-old female con-
genitally athymic (nu/nu) mice and their
hairy litter-mates wrere bred at the Imperial
Cancer Research Fund (ICRF) Laboratories.
Nude mice were bred and maintained in
sterile conditions in a negative-pressure
isolator. Hairy litter mates (nu/ +) were
maintained in conventional conditions.
Cell lines.-Human pancreatic exocrine
adenocarcinoma cells (GER) and a normal
human fibroblast cell line derived from the
same tumour tissue (GF) were cultured and
harvested as previously described (Grant et
al., 1979). Human foetal pancreatic fibro-
blasts (FB) derived from a 9-week-old
embryo (Tissue Bank, Royal Marsden Hos-
pital, London) and a fibroblast cell line from
a second pancreatic tumour (HF) were
established in a similar way.
Lymphoblastoid and myeloid cell lines
HSB2 (Adams et al., 1968) and HL60 (Collins
et al., 1979), and a breast carcinoma line
MDA-157 (Young et al., 1974) were obtained
from P. Beverley, ICRF, London. Human
urinary-bladder carcinoma cell lines SCaBer
(O'Toole et al., 1976), TCC-sup (Nayak et al.,
1977), J82 (O'Toole et al., 1978), T-24
(Bubenik et al., 1973), a line ofnon-malignant
bladder epithelium, HCV-29 (derived by
J. Fogh), and a colon-carcinoma cell line
HT-29 (Fogh & Trempe, 1975) were kindly
provided by C. O'Toole, London Hospital
Medical College. Peripheral-blood lympho-
cytes (PBL) were isolated from the blood of
patients with pancreatic cancer and from
normal healthy donors. Twenty ml of blood
was collected in 1 ml 2 7% EDTA in phos-
phate-buffered saline (PBS) or was defibrin-
ated on glass beads to prevent clotting. The
cells were isolated by Ficoll-paque (Pharm-
acia) separation. Lymphocytes from one
pancreatic cancer patient were transformed
with Epstein-Barr (EBV) virus by C. O'Toole
using the method of Miller & Lipman (1973).
All cell lines were maintained in Ham's F12
medium supplemented with 10% foetal
bovine serum and harvested with 0 02%
EDTA in Ca- and Mg-free Eearle's (Flow
Laboratories).
Human tumour xenografts. Primary pan-
creatic tumour tissue (WB) or a pancreatic
adenocarcinoma cell line (GER) were used to
establish solid human tumour xenografts in
nude mice as previously described (Grant et
al., 1979). A murine tumour (MP) was in-
duced in nude mice with polyoma virus. To
establish cell lines from the xenografts, tissue
was minced with crossed scalpels and dis-
persed into 25cm2 flasks with 3 ml ofmedium.
Tumour cells formed colonies of epithelial
cells, which were passaged after 3-4 weeks.
Human or murine tumour origin was con-
firmed by chromosome analysis (Schwartz-
acher & Wolf, 1974).
Immunization of hairy litter-mates with
serum from tumour-bearing nude mice.-
Serum was collected by cardiac puncture from
20 tumour-bearing nude mice when the
tumours measured 1-25 cm2. Mice in 4 groups
(GER-A, B, D; WB) of 6 hairy litter-mates
received 0-4 ml of serum, emulsified in com-
plete Freund's adjuvant (1:1 v/v), -which was
divided between 4 sites and given s.e. on
Day 0. Two similar injections were given at
14 and 28 days, and followed by 0 4 ml serum
i.p. at 42 days. Half a ml of blood was col-
lected from the tail vein 6 days after the final
immunization, to confirm the presence of
antibody, and the mice bled out 4 days after
the test bleed. Two groups of 6 hairy litter-
mates received normal nude mouse serum
witlh the same immunization regime (Groups
F & C).
Antibodies directed against normal human
lymphocytes wTere raised in 6 CBA mice by 3
injections of 1 5x 107 PBL at 0, 7 and 21
days. This antiserum was used as a positive
control (MHL).
Alpha-foetoprotein (AFP) and carcino-
embryonic antigen (CEA) estimations.-
Tumour-bearing mouse serum AFP and CEA
levels were measured by the Protein Refer-
ence Unit, Putney Hospital, and the Depart-
ment of Clinical Immunology, Charing Cross
Hospital, respectively, using an adaptation
of the AFP radioimmunoassay method of
Nishi & Hirai (1973), and the CEA double-
antibody radioimmunoassay of Laurence et
al. (1972).
Immunofiuorescence studies.-Suspensions
of viable cells (0 5-1 x 106 cells/well) were
incubated with 50-100 ,ul hairy litter-mate
serum raised against tumour-bearing nude
mouse serum or normal nude mouse serum.
Antisera were diluted 1:5-1:20 in PBS for
use in the assay. Mouse anti-human lympho-
cyte serum (MHL), niormal nude mouse
serum (NS) and serum obtained directly from
tumour-bearing nude mice (NMG, NMW)
were also included in the study.
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Cells were incubated at 4°C for 30 min,
washed x 3 with PBS, resuspended in 50 dul
PBS and labelled with 5-10 ,ul TRIC-
conjugated anti-mouse TgG (Nordic Immuno-
logical Laboratories, Maidenhead) for 30 min
at 4°C. Cells were washed a further x 3 in
PBS, mounted in PBS/glycerol (1:1 v/v) and
examined with a Zeiss photomicroscope with
epi-fluorescent illumination.
Primary tumour tissue or xenografts were
embedded in OCT compound (Lab-Tek
Products, Miles Laboratories), snap-frozen in
isopentane/liquid N2 and stored at -70°C.
Five-,m sections were cut on a cryostat.
Fluorescence was detected using Coons' sand-
wich technique (Coons et al., 1955).
Antibody-binding assay.-Binding of 1125
anti-mouse immunoglobulin to target cells
was performed essentially as described by
Stern et al. (1978). Suspensions of viable cells
(2-5 x 105 cells/well) were incubated with
50 pl antiserum (1:5-1:625 dilution) followed
by 20 ,ul of 1125 sheep antimouse Ig (30,000
ct/min) (a gift from P. Beverley). The ratios
of counts bound with antiserum against
tumour-bearing serum to counts bound with
antiserum against normal nude mouse serum,
or of counts bound to pancreatic target cells
vs counts bound to other target cells, were
calculated. Aratio of2 or more was considered
to be significant binding.
For CEA absorption 50 pl of 1:40 dilution
of antisera was absorbed with 0-03-4 ,ug
CEA (a gift from J. Westwood, Institute of
Cancer Research, Sutton, Surrey) or 0-05-0-5
jig AFP (Dako-Immunoglobulins, Denmark)
for 15-60 min at room temperature. Antigen-
antibody complexes were removed with
Staphylococcal protein-A antibody absorbent
(Porton Down) according to the method of
Kessler (1975) before adding the cells. Anti-
sera were also absorbed with 5 x 105-2 x 107
viable cell suspensions or 0-3 34 mg normal
pancreas homogenate insolubilized in 2.5%
gluteraldehyde/PBS, for 60 min at room
temperature, before the antibody binding
assay. Protein content was estimated accord-
ing to the Lowry method.
RESULTS
Screening ofantiserafrom hairy litter-mates
for antibody against tumour cells
All hairy litter-mates immunized with
sera from nude mice bearing xenografts
derived from a pancreatic tumour cell
line (GER) or primary tumour tissue
(WB) produced antibodies which bound
to pancreatic tumour cells, as shown by
indirect immunofluorescence (Fig. 1). No
antibodies were detected in the sera of
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FIG.1. Screening antisera for antibody against pancreatic tumour cells. Individual hairy litter-mates
immunized with serum from nude mice bearing either GER or WB tumours were tested for anti-
bodies binding to cultured pancreatic (GER) or urinary bladder (TCC-sup) tumour cells. 5 x 105
cells were incubated with 50 ul of a 1:20 (fluorescence) or 1:40 (I125 binding) dilution of antisera
followed by TRIC or 1125 anti-mouse Ig as described in Methods. MHL: mouse anti-human
lymphocytes (positive control) Antisera A-D: mice immunized with GER tumour; WB: mice
immunized with WB tumour; F; mice immunized with normal nude mouse sera; NMG: immunizing
sera from mouse bearing GER tumour; NW: immunizing sera from mouse bearing WB tumour.
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Specificity of the antisera for
tumour cells
Only 5/14 hairy litter-mates ir
with tumour-bearing sera (GER)
antibodies which were selective
creatic tumour cells (binding i
when tested against 2 human urinary
bladder tumour cell lines T24 and TCC-
sup. The remainder showed higher binding
to pancreatic tumour cells, but the binding
ratios were not > 2. The results of screen-
ing the sera against TCC-sup are shown in
Fig. 1; T24 gave essentially the same bind-
ing ratios.
Screening of one of the more specific
antisera (DNM), and one of the remainder
.Sa, (ANM), against a panel of 14 different
cell lines andPBL is shown in Fig. 3. There
--5--- was considerably greater binding of the
-,-i/--, antiserum IDNM to pancreatic tumour
150 625 cells than to the other cell lines. Only the
fibroblast cell line derived from the same
a teste(l pancreatic tumour (GF) and a colonic
i cells.
carcinoma (HT-29) had binding ratios
ar-bear- <2. Although ANM showed the highest
-normal response to pancreatic tumuor cells, it
ollowed
was also bound more strongly to the other
tumour cell lines. All cell lines responded
very weakly to the serum of hairy litter-
mates immunized with normal nude mouse
th normal serum (FIR; Fig. 3). In contrast, anti-
F2L) or in serum against human lymphocytes (MHL)
tumour- showed a high level of binding; only the
V). Using murine tumour (MP) did not react with
the bind- this antiserum.
edagainst
and nor- Presence of antibodies to CEA and AFP
)etween 2 There was < 25 Hug/l of AFP in the
hen tested serum ofmice bearing a large tumour load.
* 2). This Absorption ofantiserum (DNM) with 0-05-
antitative 0-5 jug of AFP reduced binding of the
sponse of antiserum to pancreatic tumour cells by
sera from less than IO% at the highest concentration
CR) which of antigen. CEA was present in the serum
orescence of tumour-bearing animals at concentra-
Lce in the tions up to 100 jLg/l, but was only poorly
pancreatlc detected at the cell surface when tested
iary tissue with anti-CEA (Dako Products, Den-
stablished mark) by indirect immunofluorescence.
Absorption of antiserum (DNM) with
0 03-4 ,tg CEA reduced antibody binding
pancreatic maximally by 3000 after 15 min at room
temperature, at concentrations of CEA
mmunized greater than 0 8 Hg.
produced As can be seen in Fig. 4, the amount of
for pan- antiserum binding to GER, TCC, J82 and
ratio > 2) HT-29 cells was reduced by 11-24%
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FiG. 3. Binding ofantisera to tumour and normal cells. 5 x 105 cells were incubated witlh 50,u1 of 1:40
dilution of anti-tumour-bearing mouse serum (ANM, DNM), anti-normal nude mouse serum (FIR)
and mouse anti-human lymphocytes (MHL) followed by 15-20,u1 125 anti-mouse Ig (30,000 ct/min).
Cell lines are described in methods. N.D. not (letermined. Results ( ± s.e., 3 expts) are expressedl
as 1125-Ig binding per 105 cells, and as a binding ratio of counts bouind to pancreatic tumour cells
over counts boundl to other target cells.
following CEA absorption, so that the
binding ratios were maintained and DNM
antisera still retained its specificity for
pancreatic tumour cells. Absorption with
CEA did not affect the binding of MHL
to either GER, TCC, J82 or HT-29.
Absorption of antisera with normal pan-
creas and a mixed tumour-cell pool
Five x 106 viable pancreatic tumour
cells (equivalent to 1 2 mg protein) com-
pletely removed the antibody response
from 50 [lI of 1: 50 dilution of antiserum
after 1 h incubation at room temperature.
After absorption with up to 2 x 107 cells
(5 mg protein) from a mixed pool of
equivalent numbers of J82, TCC, MDA,
HT29 tumour cells, 18% of the activity
binding to pancreatic tumour cells re-
mained. 50%o binding activity remained
after absorption with 3-4 mg of a glutaral-
dehyde-insolubilized normal-pancreas ho-
mogenate, and the activity was reduced
to 16% after sequential absorption with
normal pancreas and a mixed cell pool.
Localization of the antisera in frozen tissue
sections
Positiveimmunofluorescent stainingwas
seen in sections from all primary pan-
creatic tumours and tumour xenografts
with dilutions of CEA-absorbed antiserum
up to 1:100. Areas of strong staining were
located around the malignant ductular
epithelial cells, and appeared to reflect
the degree of morphological differentiation
of the tumour; a highly anaplastic poorly
differentiated cell population (TUR) show-
ing very little staining, whereas a well
differentiated tumour (WB) was strongly
positive. Staining of normal and foetal
pancreas was found in ductular-cell areas.
All sections were negative with hairy
anti-normal nude mouse serum and gave
a general positive fluorescence with MHL.
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Fra. 4. Absorption of antisera withi CEA.
5 x I05 cells were incubatedl withi 5o p1
1 :40 dilution-of aniti-tumour-bearing mouse
sertum (DYNI, ANM) andl mouse anti-hluman
lymphocytes (AIHL). Half of the antisera
were absorbedl wvith 0-8 tzg CEA for 3()
miii before incubation. Results are the
means of 3 expeiiments.
DISCUSSION
Cross-immunization of immunocom-
petent hairy litter-mates with serum
from pancreatic tumour-bearing immuno-
deficient nude mice has led to the produc-
tion of antibodies directed against the
components released from viable human
tumour cells during growth. Nude mice
have a normal /-lymphocyte complement
(Sprent & Miller, 1972) but we were unable
to detect free antibodies against pan-
creatic tumour cells in the sera of these
tumour-bearing animals, suggesting that
antigens were produced in excess of anti-
body and that the hairy litter-mates were
challenged with both antigen and antigen-
antibody complexes.
The presence of a high titre of anti-
bodies to pancreatic tumour cells in the
polyspecific antiserum was demonstrated
by screening against a panel oftumour and
normal diploid cell lines. This showed that
the ability of immunocompetent mice t,o
produce antibodies against human cell
components varied considerably. Only
36% of the hairy litter-mates produced a
high titre of antibody to pancreatic
tumour cells. Since the animals all received
the same pooled serum from tumour-
bearing mice this is unlikely to be due to
differences in serum protein composition
and probably reflects the mixed origins of
the immunocompetent mouse population.
Preliminary studies using matched nude
and hairy litter-mates (WB) might have
overcome this problem, but were not
successful because of the small number of
animals available. These hairy litter-mates
also had a nu/ + background, and a higher
antibody titre might have been achieved
with +/+ animals.
A mixed response to the polyspecific
antiserum was shown by all the cell lines
tested, suggesting that antibodies were
also raised against common tumour-cell
markers (CEA, epithelial-cell markers)
and normal cell-surface components that
had been shed from the pancreatic tumour
cells. Release of these and other surface
components may be a normal function of
the cell, or may arise from cellular degra-
dation. We had previously reported that
pancreatic tumour cells express LHLA and
/2 on their cell surface (Pahlman et al.,
1979) and this probably explains the high
level of antibody binding to a fibroblast
cell line (GF) derived from the same
patient from whom the tumour cell
originated. Very little CEA was detected
on the pancreatic tumour cell surface but
it was present in the serum of tumour-
bearing animals which agreed with other
studies (Kim et al., 1976). However, the
antibody against CEA could be removed
from t,he sera of immunocompetent mice
GER
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by adsorption with pure CEA without any
loss of specificity against pancreatic
tumour cells. Binding to a CEA-producing
colonic carcinoma cell line (Von Kleist
et al., 1975) remained consistently high
after CEA adsorption, suggesting that
these two gastrointestinally-derived cell
lines shared a number of cell-surface
components. AFP was not detected in the
sera of tumour-bearing animals, and
adsorption with pure antigen did not
affect the antibody response.
Immunofluorescent staining of tissue
sections showed that the predominantly
antibody response was localized around
the membrane of ductular epithelial cells
in tumour tissue as well as foetal and
normal pancreas. However, the antibodies
did not appear to be primarily directed
against epithelial cells, since the 2 epi-
thelial tumour-cell lines (SCaBer and
MDA) showed only 18% and 19% respec-
tively of the binding level found for
pancreatic-cancer cells. Similarly the low
level of binding to murine polyoma-virus-
transformed cells confirmed that the anti-
bodiesspecificallyidentifiedhumantumour
components.
Absorption of the antisera with a
mixed tumour-cell pool and normal pan-
creas homogenate did not completely
abolish the antibody response against
pancreatic tumour cells, suggesting the
presence of a pancreatic tumour-specific
antigen. Although some of the antibody
response is likely to be directed against
pancreatic antigens that have already
been isolated (Schultz & Yunis, 1979
Gelder et al., 1978) it is possible that anti-
bodies may be raised against cell-surface
components not normally present in
sufficient quantities to be immunogenic.
Thus, identification of minor, but possibly
important, tumour components might be
achieved using this technique, since they
will be continually released into the serum
during tumour growth. Another of the
advantages of this cross-immunization
technique is that it offers a novel way of
subsequently producing monoclonal anti-
bodies directed against specific antigens
released from the tumour cell. Spleens
from immunized hairy litter-mates are
currently being hybridized with myeloma
cells and, since the method permits the
exploitation of qualitative and quantita-
tive differences in the recognition of
human tumour components by individual
immunocompetent mice, it is hoped that
the resulting monoclonal antibodies will
identify a variety of tumour cell-surface
components.
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